Search

Your search keyword '"Ashley L. Fowlkes"' showing total 2 results
Start Over Author "Ashley L. Fowlkes" Journal mmwr. morbidity and mortality weekly report
2 results on '"Ashley L. Fowlkes"'

1. Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022

Author

Ashley L. Fowlkes, Sarang K. Yoon, Karen Lutrick, Lisa Gwynn, Joy Burns, Lauren Grant, Andrew L. Phillips, Katherine Ellingson, Maria V. Ferraris, Lindsay B. LeClair, Clare Mathenge, Young M. Yoo, Matthew S. Thiese, Lynn B. Gerald, Natasha Schaefer Solle, Zuha Jeddy, Leah Odame-Bamfo, Josephine Mak, Kurt T. Hegmann, Joe K. Gerald, Jezahel S. Ochoa, Mark Berry, Spencer Rose, Julie Mayo Lamberte, Purnima Madhivanan, Felipe A. Pubillones, Ramona P. Rai, Kayan Dunnigan, John T. Jones, Karl Krupp, Laura J. Edwards, Edward J. Bedrick, Brian E. Sokol, Ashley Lowe, Hilary McLeland-Wieser, Krystal S. Jovel, Deanna E. Fleary, Sana M. Khan, Brandon Poe, James Hollister, Joanna Lopez, Patrick Rivers, Shawn Beitel, Harmony L. Tyner, Allison L. Naleway, Lauren E.W. Olsho, Alberto J. Caban-Martinez, Jefferey L. Burgess, Mark G. Thompson, and Manjusha Gaglani

Subjects
Health (social science), Health Information Management, Epidemiology, Health, Toxicology and Mutagenesis, General Medicine
Published
2022
Full Text
View/download PDF

2. Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022

Author

Ashley L, Fowlkes, Sarang K, Yoon, Karen, Lutrick, Lisa, Gwynn, Joy, Burns, Lauren, Grant, Andrew L, Phillips, Katherine, Ellingson, Maria V, Ferraris, Lindsay B, LeClair, Clare, Mathenge, Young M, Yoo, Matthew S, Thiese, Lynn B, Gerald, Natasha Schaefer, Solle, Zuha, Jeddy, Leah, Odame-Bamfo, Josephine, Mak, Kurt T, Hegmann, Joe K, Gerald, Jezahel S, Ochoa, Mark, Berry, Spencer, Rose, Julie Mayo, Lamberte, Purnima, Madhivanan, Felipe A, Pubillones, Ramona P, Rai, Kayan, Dunnigan, John T, Jones, Karl, Krupp, Laura J, Edwards, Edward J, Bedrick, Brian E, Sokol, Ashley, Lowe, Hilary, McLeland-Wieser, Krystal S, Jovel, Deanna E, Fleary, Sana M, Khan, Brandon, Poe, James, Hollister, Joanna, Lopez, Patrick, Rivers, Shawn, Beitel, Harmony L, Tyner, Allison L, Naleway, Lauren E W, Olsho, Alberto J, Caban-Martinez, Jefferey L, Burgess, Mark G, Thompson, and Manjusha, Gaglani

Subjects
Cohort Studies, Male, Adolescent, SARS-CoV-2, Child, Preschool, COVID-19, Humans, Vaccine Efficacy, Female, Prospective Studies, Child, BNT162 Vaccine, United States
Abstract

The BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine was recommended by CDC's Advisory Committee on Immunization Practices for persons aged 12-15 years (referred to as adolescents in this report) on May 12, 2021, and for children aged 5-11 years on November 2, 2021 (1-4). Real-world data on vaccine effectiveness (VE) in these age groups are needed, especially because when the B.1.1.529 (Omicron) variant became predominant in the United States in December 2021, early investigations of VE demonstrated a decline in protection against symptomatic infection for adolescents aged 12-15 years and adults* (5). The PROTECT

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results